0001815776-24-000029.txt : 20240325
0001815776-24-000029.hdr.sgml : 20240325
20240325204410
ACCESSION NUMBER: 0001815776-24-000029
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20240321
FILED AS OF DATE: 20240325
DATE AS OF CHANGE: 20240325
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Thunen Shelley B
CENTRAL INDEX KEY: 0001297491
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40532
FILM NUMBER: 24780705
MAIL ADDRESS:
STREET 1: C/O RXSIGHT, INC.
STREET 2: 100 COLUMBIA
CITY: ALISO VIEJO
STATE: CA
ZIP: 92656
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: LENZ Therapeutics, Inc.
CENTRAL INDEX KEY: 0001815776
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 844867570
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 445 MARINE VIEW AVE SUITE 320
CITY: DEL MAR
STATE: CA
ZIP: 92014
BUSINESS PHONE: 858-925-7000
MAIL ADDRESS:
STREET 1: 445 MARINE VIEW AVE SUITE 320
CITY: DEL MAR
STATE: CA
ZIP: 92014
FORMER COMPANY:
FORMER CONFORMED NAME: Graphite Bio, Inc.
DATE OF NAME CHANGE: 20210312
FORMER COMPANY:
FORMER CONFORMED NAME: Integral Medicines, Inc.
DATE OF NAME CHANGE: 20200622
4
1
wk-form4_1711413836.xml
FORM 4
X0508
4
2024-03-21
0
0001815776
LENZ Therapeutics, Inc.
LENZ
0001297491
Thunen Shelley B
C/O LENZ THERAPEUTICS, INC.
445 MARINE VIEW AVE SUITE 320
DEL MAR
CA
92014
1
0
0
0
0
Stock Option (right to buy)
15.05
2024-03-21
4
A
0
27000
0
A
2034-03-20
Common Stock
27000
27000
D
Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2024 Equity Incentive Plan) through each applicable date, one thirty-sixth (1/36th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean March 21, 2024.
/s/ Evert Schimmelpennink, as Attorney-in-Fact
2024-03-25